Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery: an Intervention to Decrease Immune Suppression, Metastatic Potential and Cancer Recurrence

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2007 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Tel Aviv University
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00502684
First received: July 17, 2007
Last updated: September 19, 2007
Last verified: July 2007
  Purpose

Surgery for breast cancer has a major role in enhancing long term survival and cure, but several physiological aspects associated with surgery are implicated as enhancing tumor spread and formation of distant metastases. These include: an increase in pro-angiogenic factors, direct spread of tumor cells, accumulation of grown factors, immune suppression and direct effects of anesthetics and opiate pain relievers on cancer cells. Some of these pro-metastatic mechanism may be blocked by the interventions proposed in this study, namely by administration of β-adrenergic blockers and COX2 inhibitors around the time of surgery.

Studies have shown that surgery increases levels of catecholamines and prostaglandins, which in turn may promote the release of pro-angiogenic factors such as VEGF, and enhance vascularization of micro metastases.

Opiates given for pain relief during and after surgery have been reported to enhance tumor cell division and cause immune suppression.

The immune system is significantly suppressed during surgery. This suppression has been shown to affect the systemic resistance to infection as well as neoplastic metastatic processes.

Several studies have shown that increased levels of catecholamines and prostaglandins add to the immune suppression.

Studies in rats found that peri-operative administration of the beta β-blocker propranolol together with the COX2 inhibitor etodolac significantly reduced the suppression of NK cell activity as well as the risk for distant metastases.

A recent retrospective clinical study found that among breast cancer patients treated with a combination of regional anesthesia and a COX inhibitor the recurrence rated were significantly less than among patients undergoing surgery without these two interventions.

The purpose of the proposed prospective trial is to examine if peri-operative administration of the combination of a β-blocker together with a COX2 inhibitor will prevent suppression of cellular immunity, decrease VEGF levels, and decrease cancer recurrence rates.

In the proposed study breast cancer patients will be treated with a combination of a β-blocker and COX2 inhibitor (or placebo) before, during and after surgery. (A control group of healthy women will serve as untreated controls). The variables which will be examined are: number and activity of NK cells, levels of Th1 and Th2 cytokines, serum stress hormones and angiogenic factors, and the ability of leukocytes to produce Th1 and Th2 cytokines as a result of in vitro stimulation.

In addition to these immediate parameters, long term follow up will be conducted in order to determine the effect of the intervention on long term cancer recurrence over five years.

Statistical analysis will be done using t-tests, ANOVA, and multivariate regressions, with regard to the known risk factors for recurrence such as tumor grade, lymph node involvement etc. Sample size for immunological parameters will be 40 patients in each group and 20 healthy women. Sample size for estimates of cancer recurrence at five years of follow up wiil be 460 women (230 in each group). This sample size provides a power of 80% to detect a 50% reduction in cancer recurrence at an α of 0.05.


Condition Intervention
Primary Operable Breast Cancer
Drug: Propranolol, etodolac

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Perioperative Administration of COX 2 Inhibitors and Beta Blockers in Women Undergoing Breast Cancer Surgery: an Intervention to Decrease Immune Suppression, Metastatic Potential and Cancer Recurrence

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • No. & cytotoxic activity of NK cells, levels of NKT cells, lymphocytes, monocytes and granulocytes; cytokine levels; In vitro cytokine secretion; levels of cortisol and VEGF. Cancer recurrence in 5 years [ Time Frame: 5 years ]

Estimated Enrollment: 460
Study Start Date: October 2007
  Hide Detailed Description

Detailed Description:

Scientific Background Anesthesia and surgery are stressful situations which cause neuro-endocrine, metabolic and neurological responses. Cancer surgery may cause a decrease in anti-angiogenic factors, and enable dissemination of tumor cells through manipulation of the tumor and it blood vessels, as well as local and systemic secretion of growth hormones, and immune suppression. The magnitude of the response depends on a large number of factors, including the extent of tissue injury, technique of anesthesia and type of analgesia, blood transfusions, temperature changes, psychological stress and genetic factors (1-3). The tissue damage starts a cascade of local and systemic processes which include secretion of hormones and cytokines (1).

Post operatively, suppression of several immune functions occurs, and may last for days or weeks. The cellular immunity (macrophages, NK cells, cytotoxic T lymphocytes and dendritic cells) undergo significant suppression, while the humoral immunity remains almost entirely intact (1). These changes in cell mediated immunity may impact the systemic resistance to infection as well as metastatic neoplastic processes. Specifically, NK cells have a pivotal role in defense from neoplastic processes and leukemia. Studies have shown that high levels of activity of NK cells are associated with long term survival (1). Therefore, understanding of the processes which cause post-operative immune suppression, and prevention of such suppression, are of clinical significance.

Several substances which are secreted after surgery are thought to contribute to immune suppression in general and NK cell dysfunction in particular. These include prostaglandins, catecholamines, steroids and endorphins, have all been shown to suppress several immunological functions in vitro (1). Animal studies have shown the administration of prostaglandins and catecholamines to rats suppresses NK cell activity in vivo, in association with elevated susceptibility to cancer metastases and experimentally induces leukemia (4-6).

In rats undergoing a laparotomy, peri-operative administration of β- adrenergic blockers(propranolol or nadolol) together with COX-2 inhibitors (etodolac or indomethacin) significantly abrogated the NK cell suppression as well as the enhanced susceptibility to metastases after surgery (4,7).

The mechanism of effect of prostaglandins and catecholamines on NK cells has been elucidated (1): β- adrenergic receptors and prostanoid receptors on the cell membrane cause elevated levels of intra-cellular cAMP when activated by their ligand, which in turn interferes with the NK cell cytotoxic activity against cancer cells or viral pathogens. Since the elevated intra-cellular levels of cAMP is caused by each type of receptor independently of the other, blockade of only one of these pathways will still enable an increase in intracellular cAMP levels via the other pathway, and have no effect of the suppression of cytotoxic activity. Therefore, simultaneous blockade of both pathways may be more effective. Research done in rats directly supports this hypothesis (7).

Cells of the immune system express mostly β--2 adrenergic receptors, and to a lesser degree - β--1 receptors as well (9, 10), so pharmacological blockade requires use of a no specific blocker which can block both types of receptors. The β- antagonist propranolol (Deralin) was chosen for this experiment since it is a no specific β- blocker, capable of blocking both types of receptors, as well as the extensive clinical experience with this drug and the fact that it is a relatively safe drug. The COX-2 inhibitor chosen is Etodlac (Etopan), which has the advantage of being a selective COX-2 inhibitor which is synthesized during injury and inflammation, with little effect on the COX-1 enzyme, which is associated with ongoing maintenance of tissues.

Anesthetics and opiate analgesics also cause NK cell suppression. Research in animals and in surgical patients have shown that morphine and fentanyl in analgesic or anesthetic doses cause suppression of NK cell activity, and enhanced susceptibility to breast cancer metastases in rats (11,12). Lower doses of opiates in patients have been reported to decrease the immune suppression magnitude and duration (13). Therefore, peri-operative interventions which decrease the use of opiates (or their endogenous secretion) may be clinically important factors in cancer recurrence.

In addition to immune suppression, endogenous and exogenous opiates (endorphins morphine, fentanyl) have been implicated as promoting metastatic spread and neoplastic proliferation via other mechanisms:

  • Catecholamines have been reported to increase VEGF secretion by human cancer cells, and enhance tumor cell invasion (14-16).
  • Morphine causes increased proliferation of human tumor cells and enhances tumor vascularization (17)
  • COX2 inhibitors enhance sensitivity of human tumor cells to induction of apoptosis, and decrease capillary density in cancer tissue (18, 19).

Therefore, minimization of peri-operative opiate use and prevention or blockade of prostaglandin and catecholamine effects may delay the metastatic process and the development of existing micro-metastases.

A retrospective clinical study published in 2006 indirectly supports the proposed study: In this study breast cancer patients were treated per-operatively with a COX inhibitor (diclofenac) along with local blockade of the sympathetic and pain pathways (paravertebral anesthesia). These treatments no doubt lowered the use of opiates during and after surgery. Among patients thus treated a three fold decrease in recurrence rates was found three years after surgery (21). Of note, this study quotes the previously mentioned study in rats (6,22) and involves the same interventions.

AIM The aim of the proposed study is to examine whether peri-operative administration of COX2 inhibitors with β- adrenergic blockers decreases the immune suppression around the time of surgery, decreases stress hormone and pro-angiogenic factor secretion, and is associated with a decrease in cancer recurrence rates.

The peri-operative variables which will be examined will include number and activity of NK cells in the blood, levels of Th1 and Th2 cytokines, stress hormones and pro-angiogenic factors, and Th1&2 cytokine production by leukocytes in response to in vitro stimulation. As part of the clinical monitoring meticulous recording of type and doses of analgesics given post operatively, as well as post operative pain assessment (NAS  VAS). In addition to these parameters, long term follow up will be conducted to determine long term effects of the intervention on cancer recurrence during 5 years after surgery.

Peri-operative administration of COX inhibitors and β- adrenergic blockers Routine pre medication before surgery generally includes anxiolytics such as benzodiazepines, drugs routinely taken by the patient, and additional drugs for specific indications. Preventive administration of β- blockers and COX inhibitors are recommended in the literature pertaining to anesthesia and pain. Administration of β- blockers has been shown to stabilize the cardio vascular system and decrease peri-operative ischemic events (23), while preventive administration of COX inhibitors decreases post operative pain (5). Post operative pain has significant immunological effects: it causes secretion of endogenous opiates, and is often treated with synthetic opiates such as morphine. The opiates cause a stress response, suppress immune functions and promote tumor growth and spread. Studies have shown that administration of COX inhibitors together with morphine caused a decrease in morphine requirements. Administration of COX inhibitors can help control pain by abrogation of prostaglandin mediated pain pathways while at the same time decreasing opiate requirements. An additional benefit of COX inhibitors is it's direct activity against tumor cells by enhancing apoptosis and decreasing tumor blood supply as reported in a recently published study (21). These studies indicate that peri-operative use of these drugs does not have any detrimental effects, is not associated with increased complication - and in fact may be beneficial.

Patients and Methods

Patients and treatments:

Immune system activity will be determined among 80 operated breast cancer patients, and 20 health women in the following groups:

  • Treatment arm: 40 patients undergoing elective surgery for primary breast cancer will be treated orally according to the following protocol:

    • Propranolol (Deralin) - patients will receive a low dose of 40 mg/day (4X10mg) starting two days before surgery (immediately following the first blood draw) until the evening of surgery. The first dose will be given under supervision (described later). On the morning of surgery, a single tablet of propranolol XL 80mg will be administered together with other pre-medication drugs, and will be continued once daily for three days after surgery. Pulse and blood pressure will be monitored during the first day of treatment, during the day of surgery and on the following days until discharge from the hospital (usually on the day following surgery). If pulse decreases to less than 50/min or blood pressure decreases to under 100 systolic - the dose will be halved.
    • Etodolac (Etopan) - patients will receive 600mg of etodolac XL twice a day starting two days before and continuing through two days after surgery.
  • Control arm: Fourty patients undergoing the same operations will be treated with placebo drugs on the same schedule.
  • Healthy controls: a third control arm will include 20 healthy age-matched women presenting for routine breast exams and not undergoing surgery will undergo blood tests only.

Patients will be randomized to one of the two groups, and patient, physicians and laboratory personnel will be blinded to the patient's assignment.

Dependent variables to be tested:

  1. Cytotoxic activity of NK cells against K562 target cells.
  2. Blood leukocyte levels of NK cells, NKT cells, lymphocytes, monocytes and granulocytes as determined by FACS.
  3. Serum levels of cytokines (Th1, Th2 and inflammatory): IFN-, IL-2, IL-12, IL-4, IL-10 IL-1 and IL-6.
  4. In vitro cytokine secretion by leukocytes stimulated by HPA and LPS. (IFN- IL- 2, IL-12, IL-4, IL-10 IL-1 and IL-6.)
  5. Stress hormones and angiogenic factors: levels of cortisol and VEGF.
  6. Doses of anesthetics and analgesics used during and after surgery.
  7. Cancer recurrence during 5 years (including site of recurrence). In addition to the aforementioned groups, another 190 patients will be recruited onto each group without examining immunological parameters, and will be followed only for cancer recurrence.

Eligibility criteria:

  • Women scheduled to undergo surgery for primary breast cancer.
  • Ages 20-75.
  • ASA 1-2.

Exclusion criteria:

  • Patients with renal failure (creatinin >1.5)
  • Significant heart failure (NYH ≥ 3)
  • Patients with known liver failure (known cirrhosis, liver enzymes > 1.5 times normal)
  • Asthma
  • Patients with known allergies to one of the study drugs.
  • Patients treated regularly with one of the study drugs
  • Patients treated with digoxin.
  • Peripheral vascular disease.
  • Patients within 10 years of chemotherapy for any reason.
  • Women with another malignancy other than breast cancer.

Procedure:

After obtaining Helsinki committee approval, eligible patients will receive explanations and be invited to participate in the study. Women who consent will sign the approved informed consent form.

Anesthesia procedure will include:

Standard monitoring including automated blood pressure, ECG, O2 saturation, levels of inhaled and exhaled gases Pre-medication: at anesthesiologists discretion Induction: at anesthesiologist's discretion Maintenance: at anesthesiologist's discretion (an effort will be made to minimize opiate use but without compromising on pain control).

Post operative pain management:

Patients will be given a choice of oral Paracetamol 1000 mg every 4 hours, oral Dipyrone 1000 mg every 4 hours, oral Tramadol solution 50 mg every 6 hours and combinations of the above. If needed - 5 mg of oral percocet/oxycodone syrup every 6 hours may be added. For patients who are unable to sustain oral intake, intravenous Tramal will be offered at a dose of 50-100 mg every 6 hours and if needed - morphine 0.1 mg/kg every 4 hours. This protocol is identical to the one currently used after this type of surgery.

Blood samples :

Blood samples will be obtained two days before surgery (prior to administration of study drugs or placebo), on the morning of and the morning following surgery. Blood samples will be drawn between 7:30 and 9:00 am, and will include 10 cc of peripheral blood, preferably from the ante-cubital vein.

Blood will be collected in vacuum tubes containing 30 units of heparin without preservatives, and will be transferred immediately to the neuro-immunology lab at Tel Aviv University. Laboratory evaluation of the samples will begin within 3 hours of blood drawing. The samples will be kept at room temperature.

The samples will be divided as follows:

NK cell activity testing - 2 ml FACS analysis of cells - 1 ml In vitro testing of cytokine response to LPS - 2 ml Cytokine, cortisol and VEGF levels - 5 ml (to be performed in batches at a later time - after separation of cells plasma will be kept at -80C).

Documentation and analysis of results:

Documentation:

Epidemiological data: identification (name, ID no), age, ethnic origin, background medical conditions and drugs, smoking, menstrual status and date of last menstrual period, physical activity, presence of infections or viral illnesses within last 2 weeks.

Data related to anesthesia and surgery:

Type and length of surgery, systemic administration of opioids during and after surgery (type & dose).

Cancer related parameters: Tumor size, grade, histological type, lymph node status, adjuvant therapy.

Immunological parameters: as previously detailed is three blood samples from operated patients and a single sample from the healthy controls.

Recurrence data: location, time since surgery and survival.

Statistical Analysis:

Statistical analysis will be done by ANOVA (between and within subjects) regarding the variables. Determination of specific differences between groups will be based on the PLSD test for planned comparisons, and the Scheffe test for unplanned comparisons. Chi square tests will be used as well as Kaplan-Meier survival curves for non continuous or categorical variables. In addition, Cox regressions will be calculated to evaluate the predictive ability of treatments on cancer recurrence, taking other predicting factors into account. Blood samples and immunological data will be collected for 40 patients in groups 1 & 2 and 20 healthy controls in group 3. In order to determine impact of treatment on recurrence rates a total of 230 patients will be recruited in each group. Sample size was calculated to provide an 805 power to detect a 30-50% decrease in cancer recurrence with an alpha of 0.05.

  Eligibility

Ages Eligible for Study:   20 Years to 75 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Women scheduled to undergo surgery for primary breast cancer.

    • Ages 20-75.
    • ASA 1-2.

Exclusion Criteria:

  • • Patients with renal failure (creatinin >1.5)

    • Significant heart failure (NYH ≥ 3)
    • Patients with known liver failure (known cirrhosis, liver enzymes > 1.5 times normal)
    • Asthma
    • Patients with known allergies to one of the study drugs.
    • Patients treated regularly with one of the study drugs
    • Patients treated with digoxin.
    • Peripheral vascular disease.
    • Patients within 10 years of chemotherapy for any reason.
    • Women with another malignancy other than breast cancer.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00502684

Contacts
Contact: Tanir M Allweis, MD +972-2-584-4111 ext 74268 tanir@hadassah.org.il

Locations
Israel
Hadassah Hebrew University MEdical Center Not yet recruiting
Jerusalem, Israel, 91120
Sub-Investigator: Avidan Alexander, MD         
Sub-Investigator: Carolyn F Weiniger, MD         
Sub-Investigator: Ronen Beeri, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Tel Aviv University
Investigators
Principal Investigator: Tanir M Allweis, MD Hadassah Medical Organization
Study Director: Shamgar Ben-Eliyahu, PhD Tel Aviv University, Neuroimmunology Research Unit
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00502684     History of Changes
Other Study ID Numbers: 392-22.6.07 / 2358
Study First Received: July 17, 2007
Last Updated: September 19, 2007
Health Authority: Israel: Ministry of Health

Keywords provided by Hadassah Medical Organization:
breast cancer
surgery
immune suppression
beta blockers
COX2 inhibitors

Additional relevant MeSH terms:
Breast Neoplasms
Recurrence
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Disease Attributes
Pathologic Processes
Adrenergic beta-Antagonists
Propranolol
Etodolac
Cyclooxygenase 2 Inhibitors
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Antihypertensive Agents
Vasodilator Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on April 16, 2014